ADOPTION AGREEMENT 1.01 PREAMBLE By the execution of this Adoption Agreement the Plan Sponsor hereby [complete (a) or (b)] (a) adopts a new plan as of [month, day, year] (b) amends and restates its existing plan as of 01/01/2008 [month, day, year]...Special Effective • November 5th, 2007 • King Pharmaceuticals Inc • Pharmaceutical preparations
The Plan is intended to be a “plan which is unfunded and is maintained by an employer primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees” within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of the Employee Retirement Income Security Act of 1974, as amended, or an “excess benefit plan” within the meaning of Section 3(36) of the Employee Retirement Income Security Act of 1974, as amended, or a combination of both. The Plan is further intended to conform with the requirements of Internal Revenue Code Section 409A and the final regulations issued thereunder and shall be implemented and administered in a manner consistent therewith.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN ACURA PHARMACEUTICALS, INC. AND KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.License, Development and Commercialization Agreement • November 5th, 2007 • King Pharmaceuticals Inc • Pharmaceutical preparations • New York
This LICENSE, DEVELOPMENT and COMMERCIALIZATION AGREEMENT (this “Agreement”), having a date of October 30, 2007 (the “Execution Date”), is made by and between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having its principal place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and King Pharmaceuticals Research and Development, Inc. (“King”), a Delaware corporation and wholly owned subsidiary of King Pharmaceuticals, Inc., having a place of business at 4000 CentreGreen Way, Cary, NC 27513.
